Other languages EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Real-time Estimate Cboe BZX Other stock markets 01:20:24 01/05/2024 am IST			5-day change	1st Jan Change
17.74 ^USD	+0.65%		+0.71%	-23.43%

02/04	EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	CI
18/03	EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02/04
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/03
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	05/03
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	04/03
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	04/02
Eyepoint Pharmaceuticals Insider Sold Shares Worth $1,265,539, According to a Recent SEC Filing	31/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing	30/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $297,621, According to a Recent SEC Filing	27/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $409,790, According to a Recent SEC Filing	26/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $795,191, According to a Recent SEC Filing	25/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $484,124, According to a Recent SEC Filing	11/01
EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema	10/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	08/12
EyePoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	08/12
Eyepoint Pharmaceuticals Insider Sold Shares Worth $990,000, According to a Recent SEC Filing	07/12
Eyepoint Pharmaceuticals Insider Sold Shares Worth $415,200, According to a Recent SEC Filing	07/12
EyePoint Pharmaceuticals Prices Offering of 11.8 Million Shares to Fund Macular Degeneration Study	06/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Other languages

Filters